Diamyd Medical AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DMYD-B.ST research report →
Companywww.diamyd.com
Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013.
- CEO
- Ulf Hannelius
- IPO
- 2013
- Employees
- 30
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $159.72M
- P/E
- -0.82
- P/S
- 443.68
- P/B
- 0.97
- EV/EBITDA
- -0.26
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -11588.89%
- Op Margin
- -58405.28%
- Net Margin
- -55685.56%
- ROE
- -79.70%
- ROIC
- -98.85%
Growth & Income
- Revenue
- $130.00K · 0.00%
- Net Income
- $-169,777,000 · -11.81%
- EPS
- $-1.51 · 5.63%
- Op Income
- $-183,236,000
- FCF YoY
- -30.99%
Performance & Tape
- 52W High
- $17.88
- 52W Low
- $0.90
- 50D MA
- $4.34
- 200D MA
- $10.08
- Beta
- 2.33
- Avg Volume
- 3.35M
Get TickerSpark's AI analysis on DMYD-B.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our DMYD-B.ST Coverage
We haven't published any research on DMYD-B.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DMYD-B.ST Report →